I’m not scared about the investors. Finnish biotech start - up Nightingale is looking to pick up where Theranos left off , by providing diagnostic medicine with its magnetic resonance biomarker test . Nightingale 's blood analysis platform analyses the data of a vast number of samples to help with risk prediction of chronic diseases such as type 2 diabetes . CEO Teemu Suna said that , unlike Theranos , Nightingale prefers to share its results and remain open to peer scrutiny , adding that its rival 's success had put off competition in the sector .
Finnish biotech start - up Nightingale is looking to pick up where Theranos left off , by providing diagnostic medicine with its magnetic resonance biomarker test . Nightingale 's blood analysis platform analyses the data of a vast number of samples to help with risk prediction of chronic diseases such as type 2 diabetes . CEO Teemu Suna said that , unlike Theranos , Nightingale prefers to share its results and remain open to peer scrutiny , adding that its rival 's success had put off competition in the sector .